Review of the Fialuridine (FIAU) Clinical Trials

Review of the Fialuridine (FIAU) Clinical Trials

By: Institute of Medicine (author), Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials (author), National Academy of Sciences (author), National Research Council (author), Martin Swartz (editor), Frederick J. Manning (editor)Paperback

Up to 2 WeeksUsually despatched within 2 weeks

Description

In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants. In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.

About Author

Frederick J. Manning and Morton Swartz, Editors; Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials, Institute of Medicine

Contents

1 Front Matter; 2 Executive Summary; 3 Introduction; 4 Clinical Trials; 5 Hepatitis B and Other Viral Diseases; 6 Clinical Trials of FIAC at Memorial Sloan-Kettering Cancer Center; 7 Oclassen Clinical Trial R89-001-01; 8 Oclassen Clinical Trial R90-001-01 (NIH Protocol 91-AI-0031); 9 Oclassen Clinical Trial R91-001-10 (NIH Protocol 91-DK-AI-213); 10 Eli Lilly Trial H3X-MC-PPPA; 11 Eli Lilly Trial H3X-MC-PPPG; 12 Eli Lilly Trial H3X-MC-PPPC (NIH Protocol 93-DK-0031); 13 Summary of Patient Interviews; 14 Overall Assessment of the Trials; 15 Recent Studies of FIAU Toxicity; 16 Review of the FDA Task Force Report 'Fialuridine: Hepatic and Pancreatic Toxicity'; 17 Review of 'Report to the Advisory Committee to the Director, National Institutes of Health'; 18 FDA-Proposed Changes to the Code of Federal Regulations; 19 Ancillary Issues Raised During the Period Following The H3X-MC-PPPC Trial; 20 Conclusions and Recommendations; 21 Appendix A: Chronology of FIAU/FIAC Clinical Trials; 22 Appendix B: Bibliography and References; 23 Appendix C: Agendas from the Three Committee Meetings; 24 Appendix D: Informed Consent Documents; 25 Appendix E: Example of Oclassen Fax Data Summaries; 26 Appendix F: FIAC and FIAU Preclinical Toxicity Studies; 27 Appendix G: Patient Summaries, Lilly Trial H3X-MC-PPPA; 28 Appendix H: Statistical Analysis of Mortality in the FIAU/FIAC Clinical Trials; 29 Glossary

Product Details

  • ISBN13: 9780309052795
  • Format: Paperback
  • Number Of Pages: 280
  • ID: 9780309052795
  • ISBN10: 0309052793

Delivery Information

  • Saver Delivery: Yes
  • 1st Class Delivery: Yes
  • Courier Delivery: Yes
  • Store Delivery: Yes

Prices are for internet purchases only. Prices and availability in WHSmith Stores may vary significantly

Close